Results 131 to 140 of about 22,234 (251)

Defining Polysaccharide-Specific Antibody Targets against Vibrio cholerae O139 in Humans following O139 Cholera and following Vaccination with a Commercial Bivalent Oral Cholera Vaccine, and Evaluation of Conjugate Vaccines Targeting O139

, 2021
Mohammad Kamruzzaman, Meagan Kelly, Richelle C. Charles, Jason B. Harris, Stephen B. Calderwood, Aklima Akter, Rajib Biswas, M. Hasanul Kaisar, Taufiqur Rahman Bhuiyan, Louise C. Ivers, Ralph Ternier, Jean-Gregory Jerome, Hélène B. Pfister, Xiaowei Lu, Sameh E. Soliman, Bart Ruttens, Rina Saksena, Jana Mečárová, Alžbeta Čížová, Firdausi Qadri, Slavomı́r Bystrický, Pavol Kováč, Peng Xu, Edward T. Ryan   +23 more
openalex   +1 more source

Onset and Duration of Protective Immunity in Challenged Volunteers afterVaccination with Live Oral Cholera Vaccine CVD l03-HgR [PDF]

, 2017
CVD 103-HgR is a liveoral cholera vaccinethat, in phase I and II studies to date, has been well tolerated and immunogenic. In challenge studies of US volunteers conducted 4-5 weeks after vaccination, CVD 103-HgR provided significant protection against ...
Cryz, Stanley J., Edelman, Robert, Kaper, James B., Levine, Myron M., Losonsky, Genevieve, Nataro, James P., Tacket, Carol O.   +6 more
core  

Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels [PDF]

, 1993
Eduardo Gotuzzo, Betzabé Butrón, Carlos Seas, Mary E. Penny, R Ruiz, G Losonsky, Claudio F. Lanata, Steven S. Wasserman, Eduardo Salazar, James B. Kaper   +9 more
openalex   +1 more source

Challenges for Programmatic Implementation of Oral Cholera Vaccine in India. [PDF]

J Infect Dis, 2021
Chakraborty D, Kanungo S, Kumar Nandy R, Kumar Deb A, Kumar Mukhopadhyay A, Dutta S.   +5 more
europepmc   +1 more source

An Age-stratified, Randomized Immunogenicity Trial of Killed Oral Cholera Vaccine with Delayed Second Dose in Cameroon. [PDF]

Am J Trop Med Hyg, 2022
Ateudjieu J, Sack DA, Nafack SS, Xiao S, Tchio-Nighie KH, Tchokomeni H, Bita'a LB, Nyibio PN, Guenou E, Mondung KM, Dieumo FFK, Ngome RM, Murt KN, Ram M, Ali M, Debes AK.   +15 more
europepmc   +1 more source

Vaccination of Cows with a Combined Rotavirus/Enterotoxigenic "E. Coli" K99 Vaccine to Protect Newborn Calves Against Diarrhoea [PDF]

, 1983
Bachmann, P. A., Baljer, G., Eichhorn, Werner, Plank, P., Schneider, P.   +4 more
core   +1 more source

A 6-Week Oral Toxicity Study of Oral Cholera Vaccine in Sprague-Dawley Rats

, 2012
Yeong-Ok Baek, Seuk-Keun Choi, Seo‐Ho Shin, Kyo-Hwan Koo, Ho-Young Choi, Seung-Bum Cha, Yongchun Li, Hyeon-Jeong Yoo, Jooyoung Lee, Ki-Hyun Kil, Hak‐Soo Kim, Minsoo Kang, Boo-Hyun Kang, Kap-Ho Kim, Jin-Sook Bae   +14 more
openalex   +2 more sources

Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR in healthy adults age 18–45

, 2018
James McCarty, Michael Lock, Kristin M. Hunt, Jakub K. Simon, Marc Gurwith   +4 more
openalex   +1 more source

A scoping review of facilitators and barriers influencing the implementation of surveillance and oral cholera vaccine interventions for cholera control in lower- and middle-income countries. [PDF]

BMC Public Health, 2023
Trolle H, Forsberg B, King C, Akande O, Ayres S, Alfvén T, Elimian K.   +6 more
europepmc   +1 more source

Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection WithVibrio choleraeO1 El Tor [PDF]

, 2016
Wilbur H. Chen, Mitchell B. Cohen, Beth D. Kirkpatrick, Rebecca C. Brady, David Galloway, Marc Gurwith, R. H. Hall, Robert A. Kessler, Michael Lock, Douglas J. Haney, Caroline E. Lyon, Marcela F. Pasetti, Jakub K. Simon, Flóra Szabó, Sharon M. Tennant, Myron M. Levine   +15 more
openalex   +1 more source